HPTN 083-02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study

By sjmartinez • May 24, 2024

Psaros C, Goodman GR, Lee JS, Rice W, Kelley CF, Oyedele T, Coelho LE, Phanuphak N, Singh Y, Middelkoop K, Griffith S, McCauley M, Rooney J, Rinehart AR, Clark J, Go V, Sugarman J, Fields SD, Adeyeye A, Grinsztejn B, Landovitz RJ, Safren SA; HPTN 083‐02 Study Team. HPTN 083-02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study. J Int AIDS Soc. 2024 May;27(5):e26252. doi: 10.1002/jia2.26252. PMID: 38783534.

Tags: HIV prevention, Infectious Diseases, Injectable PrEP, Men who have sex with men, pre‐exposure prophylaxis, Publications, qualitative, Transgender women

Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with multidrug resistant HIV-1: A phase 3, multicenter, expanded access study

Emu B, Kumar PN, Mills A, Berhe M, Cash BR, Kuo KL, Anstett K. Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with[...]

Estimated Burden of Coccidioidomycosis

Williams SL, Benedict K, Jackson BR, Rajeev M, Cooksey G, Ruberto I, Williamson T, Sunenshine RH, Osborn B, Oltean HN, Reik RR, Freedman MS, Spec[...]

Barriers to viral suppression in children aged 9 years or younger on dolutegravir-based antiretroviral therapy in Malawi, a mixed-methods study

Phiri K, Hagstrom C, Lungu E, Balakasi K, Songo J, Makwaya A, Smith D, Worku A, Hoffman R, Phiri S, Dovel K, van Oosterhout JJ.[...]